147

therapeutic
published patents

56

oncology
published patents

310

research tools

46

diagnostic
published patents

Our Technology Offers

Welcome to our Technology Offers website

You want access to an innovative offer which is based on the excellence of Inserm, the leading academic research and clinical institute dedicated to human health in Europe? Find out our technologies offers of patents and research tools: here is a sample of our patents.

Applications
Therapy areas
Download
More posts

Novel melanoma antigens

The invention relates to melanoma antigen named MELOE and their use for preventing, treating and diagnosing melanoma. […]

Apelin for the treatment of type 2 diabetes

Use of Apelin in humans has a positive effect on insulin sensitivity with a good tolerance and a good safety. Thus, a first object of the invention […]

A b cell depleting agent for the treatment of atherosclerosis or post

New anti-atherogenic strategies based on B cell modulation, and suggest that patients currently treated with CD20 antibodies for other immune-mediated […]

Methods and pharmaceutical compositions for the treatment of acute

An easily administrable drug treatment to increase the recanalization rate associated with intravenously t-Pa would represent a major advance in the […]

Methods and compositions for treating pulmonary alveolar proteinosis

The present invention relates to a method for treating pulmonary alveolar proteinosis related to MARS gene mutations in a subject in need thereof […]

Use of il-6 inhibitors for the treatment of acute chest syndrome in

Acute chest syndrome (ACS) is a common and potentially lethal form of acute lung injury in sickle cell disease (SCD). Because pathophysiology remains […]

Methods and compositions for promoting wound healing in a subject

The present invention relates to a method for promoting wound healing in a subject suffering from Ectodermal dysplasia in need thereof comprising a […]

Novel melanoma antigen peptide and uses thereof

The invention relates to peptides derived from the MELOE antigen for therapeutic vaccination against cancer. A phase I clinical trial for ex-vivo […]

You might also be interested in

Contact

Inserm Transfert

Research tool licensing team

researchtools@inserm-transfert.fr